A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-Manifest Huntington's Disease.

Trial Profile

A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-Manifest Huntington's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Ubidecarenone (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions; Biomarker
  • Acronyms PREQUEL
  • Most Recent Events

    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
    • 20 Jun 2013 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top